Search research articles
Contact Us
Filters
Showing results (431-440 of 703) with videos related to
Page
of 71
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)
Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
The New England Journal of Medicine
|
April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 24, 2020
Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
Jenny H Lee, Alexander M Menzies, Matteo S Carlino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Nature Medicine
|
June 21, 2024
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF<sup>V600</sup>-mutant resectable melanoma: the randomized phase 2 NeoTrio trial
Georgina V Long, Matteo S Carlino, George Au-Yeung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2017
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma
Ricardo E Vilain, Alexander M Menzies, James S Wilmott, et al.
The Lancet. Oncology
|
June 9, 2017
Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A Davies, Philippe Saiag, Caroline Robert, et al.
Page
of 71
Search research articles
Search
Showing results (431-440 of 703) with videos related to
Sort By:
Page
of 71
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)
Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, et al.
The Lancet. Oncology
|
April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF<sup>V600E</sup> or BRAF<sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Dirk Schadendorf, Axel Hauschild, Mario Santinami, et al.
The New England Journal of Medicine
|
April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 24, 2020
Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
Jenny H Lee, Alexander M Menzies, Matteo S Carlino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2025
Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Georgina V Long, Evan J Lipson, F Stephen Hodi, et al.
Nature Medicine
|
June 21, 2024
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF<sup>V600</sup>-mutant resectable melanoma: the randomized phase 2 NeoTrio trial
Georgina V Long, Matteo S Carlino, George Au-Yeung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2017
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma
Ricardo E Vilain, Alexander M Menzies, James S Wilmott, et al.
The Lancet. Oncology
|
June 9, 2017
Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A Davies, Philippe Saiag, Caroline Robert, et al.
Page
of 71